SYDNEY, AUSTRALIA--(Marketwired - Apr 6, 2014) - Prima BioMed Ltd (
A live webcast of the presentation can be accessed via Prima's website at www.primabiomed.com.au or via the conference webcast service website at http://wsw.com/webcast/needham65/PBMD/. A replay will be available approximately one hour after the presentation.
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell- based product currently in clinical trials. www.primabiomed.com.au
Contact Information:
For further information please contact:
USA Investor/Media:
Adam Holdsworth
ProActive Capital
+1 (646) 862 4607
Australia Investor/Media:
Mr Matthew Gregorowski
Citadel Communications
+61 (0) 422 534 755
Europe Investor/Media:
Mr. Axel Mühlhaus
edicto GmbH
+49 (0) 69 905505-52
Prima BioMed Ltd
Level 7, 151 Macquarie Street
Sydney NSW 2000
Phone: +61 2 9276 1224
Fax: +61 2 9276 1284
www.primabiomed.com.au
ABN: 90 009 237 889